NCT05878704
Study of GBT021601 in Participants With Renal Impairment
A Phase I, Open-Label, Single-Dose, Non-Randomized, Parallel Group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of GBT021601, an Oral Hemoglobin S Polymerization Inhibitor, in Adult Participants With Renal Impairment
Pfizer·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Renal Impairment
- Drug/Device/Intervention
- GBT021601
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Pfizer
- Location
- Tustin,Miami, United States of America
Timeline & enrollment
- Phase
- Phase 1
- Start date
- Jun 29, 2023
- End date
- Jul 09, 2024
- Enrollment
- 56 participants
Primary outcome
Concentration of GBT021601 in whole blood and plasma,Single-dose PK parameters
Summary
Renal Impairment study of GBT021601.
ICD-10 classifications
Renal failureDisorders resulting from impaired renal tubular functionDisorder resulting from impaired renal tubular function, unspecifiedOther disorders resulting from impaired renal tubular functionAcute renal failure
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05878704
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT05878704 through Pure Global AI's free database. This Phase 1 trial is sponsored by Pfizer and is currently Recruiting. The study focuses on Renal Impairment. Target enrollment is 56 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.